相关实验视频

Updated: Sep 13, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

局部5-甲作为阿梅洛母细胞瘤的新型辅助疗法

Jing-Rui Yi¹, Gui-Lin Liu², Qi-Wen Man^1,3

¹The State Key Laboratory of Oral and Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School and Hospital of Stomatology, Wuhan University, Wuhan.

The Journal of craniofacial surgery

|August 1, 2025

概括

局部使用的5-甲 (5-FU) 显示出治疗外科切除后乳腺母细胞瘤的前景. 这种方法导致两年内4例病例没有复发,表明其潜在的有效性.

科学领域:

在瘤学瘤学.
口腔和牙面部外科手术
药理学药理学是指药理学的学科.

背景情况:

骨髓母细胞瘤的治疗通常涉及切割或 marsupialization.
这些初级治疗具有很高的复发率.
需要新的治疗策略来改善乳腺母细胞瘤的管理.

研究的目的:

评估局部5-甲 (5-FU) 作为阿梅洛母细胞瘤辅助疗法的疗效.
为了评估治疗的乳腺母细胞瘤的复发率,其次是局部5-FU.
为了研究局部5-FU对乳腺母细胞瘤组织的细胞效应.

主要方法:

一系列病例包括4名阿梅洛母细胞瘤患者,接受了除治疗,随后是局部5-甲 (5-FU) 治疗.
传输电子显微镜被用来检查5-FU治疗的乳腺母细胞瘤组织中的细胞变化.
进行了临床随访,以监测复发情况.

主要成果:

在切割后局部5-FU应用表明在治疗乳腺母细胞瘤方面具有潜在的有效性.
传输电子显微镜揭示了在5-FU治疗的乳腺母细胞瘤细胞中的亡.
在2年的随访期间,在4例病例中没有观察到乳腺母细胞瘤的复发.

结论:

局部使用的5-甲 (5-FU) 是一个有前途的治疗模式,用于乳腺母细胞瘤,当使用后切.
这种辅助疗法似乎可以有效地预防复发.
需要进一步的研究,以在更大的研究中证实这些发现.

关键词:

5-FU的使用情况.在CBCT中,CBCT是CBCT.艾梅洛母细胞瘤 (Ameloblastoma) 是一种灭症 (apoptosis) 是一种死亡的过程.复发性复发性复发性

更多相关视频

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...